Gyeonggi Boosts Bio Startup US Expansion Support

**Gyeonggi Bio Startups, Beyond Boston to the World! 'Step-by-Step Investment Attraction Program' for US Market Entry Officially Launched** Gyeonggi bio startups have embarked on a bold challenge towards Boston, USA, the heart of the global bio market. Gyeonggi Province's ambitious '2025 US Bio Investment Attraction Capacity Building Program' took its successful first step on the 24th, signaling the start of a journey for local innovative companies to establish themselves in the US market. This program, hosted by Gyeonggi Business & Science Accelerator (GBSA) and operated by bio accelerator Genexis, focuses on intensively strengthening IR (investor relations) capabilities to help Gyeonggi companies gain competitiveness and succeed in attracting local US investment and entering the market amidst the rapidly changing global bio market. This is a core part of Gyeonggi Province's bio industry fostering policy, aimed at selecting and intensively nurturing local startups with global expansion potential. Like a well-structured navigation system, this program presents a meticulous 8-step roadmap. It spans from ▲precise company diagnosis to ▲expert 1:1 IR consulting, ▲fluent English pitching consulting, ▲creation of persuasive English IR materials, and ▲support for eye-catching IR design. Not stopping there, comprehensive, step-by-step support offering practical investment attraction opportunities unfolds, including direct participation in US Boston conferences—the mecca of the global bio industry—local demo days, and online investor relations meetings for global investors. Genexis plans to enhance the chances of success by providing optimized, customized accelerating strategies based on each company's characteristics and diagnostic results. During the orientation on the 24th, detailed program information was provided, along with enthusiastic introductions and networking among participating companies. The program also began with an in-depth approach from the outset, through education on US bio investment market trends and diagnostics on each company's global expansion readiness. The final 10 companies embarking on this challenge are a treasure trove of innovative technologies that will shape the future of Gyeonggi's bio ecosystem. Their profiles are as follows: ▲Deepson Bio (non-invasive brain disease treatment devices), ▲Radahaim (organoid automation platform), ▲Raon Medi (AI-based dental imaging diagnosis), ▲Revomed (medical device R&D), ▲Vascular Interface (blood-contacting medical devices), ▲Billix (bilirubin-based rare disease new drugs), ▲IsenTech (point-of-care diagnostic platform), ▲AINB (AI-based antibody therapeutics), ▲Exosystems (AI digital biomarkers), ▲Oland Bio (tissue regeneration medical technology). Boasting unique technological prowess in their respective specialized fields, these companies are poised to create a new sensation in the US market. GBSA and Genexis pledged successful outcomes, stating, "This program will go beyond simple education, focusing all efforts not only on practical capacity building to enable participating companies to attract actual overseas investment and expand into markets, but also on establishing a sustainable support system." Expectations are high for the ascent of Gyeonggi bio startups as they elevate the status of K-Bio on the world stage.